Response to Bevacizumab for the treatment of Rendu-Osler disease-A note of caution

Liver Int. 2017 Jun;37(6):928. doi: 10.1111/liv.13385.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bevacizumab*
  • Humans
  • Telangiectasia, Hereditary Hemorrhagic*

Substances

  • Bevacizumab